司来吉兰联合多奈哌齐治疗帕金森病患者的临床疗效

Clinical Effect of Selegiline and Donepezil in the Treatment of Parkinson’s Disease

目的探讨司来吉兰联合多奈哌齐治疗帕金森病患者的临床疗效。方法选取2018年1月至2020年3月辽宁省健康产业集团阜新矿总院收治的帕金森病患者92例为研究对象,随机分为对照组与观察组,各46例。对照组患者给予司来吉兰治疗,观察组患者采用多奈哌齐与司来吉兰联合治疗。比较两组患者治疗效果、氧化应激水平、简易智能精神状态检查量表(MMSE)评分、蒙特利尔认知评估量表(MoCA)评分、帕金森病综合评分量表(UPDRS)评分及不良反应发生率。结果观察组治疗有效率为93.48%,低于对照组的78.26%,差异有统计学意义(P<0.05);治疗后,观察组患者谷胱甘肽、超氧化物歧化酶高于对照组,丙二醛低于对照组,差异有统计学意义(P<0.05);治疗后观察组患者MMSE评分、MoCA评分高于对照组,UPDRS评分低于对照组,差异有统计学意义(P<0.05);观察组患者不良反应发生率是8.68%,低于对照组的13.03%,但差异无统计学意义(P>0.05)。结论对帕金森病患者予以多奈哌齐与司来吉兰联合治疗,能取得较好的治疗效果,减轻氧化应激反应,运动功能、认知功能和精神状态改善,减少不良反应发生率,促进机体康复。

Objective To explore the effect of donepezil combined with selegiline in the treatment of patients with Parkinson’s disease. Methods A total of 92 patients with Parkinson’s disease admitted to Fuxin Mining General Hospital from January 2018 to March 2020 were selected as the research objects, and were randomly divided into a control group and an observation groups with 46 cases in each group. Patients in the control group were given selegiline, and patients in the observation group were given donepezil combined with selegiline. The therapeutic effect, oxidative stress level, MMSE score, MOCA score, UPDRS score and adverse reaction rate of the 2 groups were compared. Results The total effective rate of the control group was 78.26%, lower than 93.48% of the observation group, the difference was statistically significant(P<0.05);after treatment, glutathione and superoxide dismutase in the observation group were higher than those in the control group, and malondialdehyde was lower than the control group, the difference was statistically significant(P<0.05);after treatment, the MMSE score and MOCA score of the observation group were lower than those of the control group, and the malondialdehyde was lower than the control group, the difference was statistically significant(P<0.05). The incidence of adverse reactions in the observation group was 8.68%, which was lower than 13.03% in the control group, but the difference was not statistically significant(P>0.05). Conclusion Donepezil combined with selegiline in the treatment of patients with Parkinson’s disease can achieve good therapeutic effect, reduce the level of oxidative stress, improve motor function, cognitive function and mental state, reduce the incidence of adverse reactions, and promote the recovery of the body.